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CNS Central nervous system 
DI Disposition index 
FPG Fasting plasma glucose 
FPIR First-phase insulin release  
GCK Glucokinase 
RFX6 Regulatory factor X, 6 
HNF Hepatocyte nuclear factor 
GWAS  Genome-wide association study 
GLP-1 Glucagon-like peptide-1 
G6PC2 Glucose-6-phosphatase 2 
GIP Glucose-dependent insulinotropic peptide (formerly, gastric inhibitory peptide) 
HbA1c Glycated hemoglobin 
HOMA Homeostasis model assessment 
HOMAβ HOMA-derived index of beta-cell function 
HOMA-IR HOMA-derived index of insulin resistance 
HGC Hyperglycemic clamp 
HEC Hyperinsulinemic-euglycemic clamp 
ISI Insulin sensitivity index 




IVGTT Intravenous glucose tolerance test 
MODY Maturity onset diabetes of the young 
MTNR1B  Melatonin receptor 1B  
MAF  Minor allele frequency 
MMTT Mixed meal tolerance test  
OR Odds ratio 
OGTT Oral glucose tolerance test 
PTV Protein-truncating variant 
SLC30A8 Solute carrier family 30, member 8 
T1D Type 1 diabetes 
T2D Type 2 diabetes 
ZnT8  Zinc transporter 8 






The last decade has revealed hundreds of genetic variants associated with type 2 diabetes, many 
especially with insulin secretion. However, the evidence for their single or combined effect on beta-
cell function relies mostly on genetic association of the variants or genetic risk scores with simple 
traits, and few have been functionally fully characterized even in cell or animal models. Translating 
the measured traits into human physiology is not straightforward: none of the various indices for 
beta-cell function or insulin sensitivity recapitulates the dynamic interplay between glucose-
sensing, endogenous glucose production, insulin production and secretion, insulin clearance, 
insulin resistance – to name just a few factors. Since insulin sensitivity is a major determinant of 
physiological need of insulin, insulin secretion should be evaluated in parallel with insulin 
sensitivity. On the other hand, multiple physiological or pathogenic processes can either mask or 
unmask subtle defects in beta-cell function. Even in monogenic diabetes, a clearly pathogenic 
genetic variant can result in different phenotypic characteristics – or no phenotype at all. In this 
review, we evaluate the methods available for studying beta-cell function in humans, critically 
examine the evidence linking some identified variants to a specific beta-cell phenotype and 





Beta-cell dysfunction can involve different dysregulated processes including glucose sensing, 
response to secretory potentiators and inhibitors, proinsulin production and processing, insulin 
granule exocytosis etc. [1]. In humans, these cannot be studied directly in vivo. Instead, insulin 
secretion, either at fasting or after stimulus, is estimated from indices calculated from circulating 
peripheral concentrations of glucose and insulin or C-peptide. Most commonly insulin secretion is 
stimulated by oral glucose or test meal, but different intravenous (i.v.) secretagogues can also be 
used, including glucose, glucagon, arginine, GIP, GLP-1 or sulphonylurea (tolbutamide) [2–8]. 
Unfortunately i.v. sulphonylurea, GIP or GLP-1 preparations for human in vivo use are not 
available at present. Further, a graded glucose infusion has been combined with arginine boluses, 
sometimes potentiated with GLP1-infusion, which seems to be the best estimate of the maximal 
insulin secretory capacity [9].   
The stimulatory tests can serve at least three purposes. Firstly, a low level of a hormone does not 
necessarily signify secretory insufficiency, but it can also derive from lack of demand. Hence, 
insulin levels of a very insulin-sensitive euglycaemic individual can be very low, while similar levels 
combined with high glucose reflect defective insulin secretion. Adding a stimulus for insulin 
secretion will bring out the difference in beta-cell function between these two alternatives.  
Secondly, with stimulatory tests we can try to differentiate whether defective insulin secretion is the 
result of reduced beta-cell mass or defective function of beta-cells. It needs emphasizing that most 
tests cannot distinguish between these defects. Nonetheless, comparison of insulin responses to 
different secretagogues, for example sulphonylureas (SUs) and glucose, can provide indirect 
evidence: a sufficient response to some secretagogue but not to another signifies functionality of 
the defect. On the other hand, if no response is elicited by any secretagogue, the beta-cells are 
presumably non-existent. Pancreatic imaging is of help only in case of major structural defects. 
Ultrasound, computed tomography  or magnetic resonance imaging (MRI) can detect total or 
partial pancreatic aplasia, as well as signs of marked acute or chronic pancreatitis, whereas 
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functional imaging with positron emission tomography employing a radiolabeled GLP1-analogue, 
single-photon emission computed tomography, and cation-enhanced MRI allow focusing on 
pancreatic islets [10,11]. However, even these methods are incomplete regarding 
sensitivity/specificity, spatial resolution or tissue penetration of the radioligand, and none of the 
imaging modalities specifically detects beta-cell mass [12,13]. Nor is the detection of beta-cell loss 
possible in vivo, as pancreatic biopsies are not available due to complications associated with the 
procedure. Even post-mortem studies are few [14,15]. 
 
To detect subtle defects in beta-cell mass or function, a secretory stimulus combined with blood 
sampling at multiple time-points may be required. For minute effects, a combination of different 
stimuli (e.g. glucose and arginine) may be necessary to tease out a difference. Another possibility 
to unmask subtle changes in beta cell function would be to increase the need of insulin. Obviously, 
we cannot modify the degree of insulin resistance in humans with high-fat diet, restriction of 
movement or other methods applied in animal studies. A natural increase in insulin resistance 
during pregnancy could provide a powerful setup for physiological studies on variants affecting 
beta-cell dysfunction, if large enough cohorts with gestational diabetes were available. In line with 
this, monogenic diabetes is often exposed during pregnancy [16]. 
 
Thirdly, the use of different stimuli can reveal qualitative differences in beta-cell function. Thus the 
choice of a stimulus depends on whether the interest lies in glucose-responsiveness, incretin 
response or other processes. Briefly, glucose stimulates insulin secretion through the KATP channel 
closure and membrane depolarization. The insulinotropic incretins, GIP and GLP-1, act directly on 
GIP receptor and GLP-1 receptor and potentiate glucose-mediated insulin secretion by increasing 
intracellular cAMP levels and thus the KATP channel activity [17]. Also glucagon, binding to 
glucagon receptors and GLP-1 receptors, elicits glucose-mediated insulin secretion [4]. On the 
other hand, sulphonylureas directly close the KATP channel independently of glucose; genetic 
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variation in the KATP channel can modify the response to sulphonylureas. However, arginine has an 
effect independent of both glucose and the KATP channel. Being a positively charged amino acid, it 




Functional characterization of a genetic variant, which is presumed to affect beta-cell function, 
usually involves engineering the mutation in beta-cell lines, induced pluripotent stem cell lines 
differentiated into beta-cells, or global/tissue-specific knock-out or knock-in animal models. These 
models have a controlled genetic background, which allows of testing the specific effect of a single 
variant. On the contrary, in humans, besides the variant of interest also all other variation in the 
genome and epigenome modulates the studied trait – together with the effects of life-style. Co-
occurring variants can also have opposite effects on the trait, which can mask the true effect of the 
variant of interest, as we recently showed for variants in SLC30A8 [18]. Another example is the 
common p.Val219Leu variant in G6PC2, which is associated with reduced G6PC2 protein 
expression and reduced fasting plasma glucose in vitro, but paradoxically with higher glucose at a 
population-level [19]. The rationale is that the glucose-lowering coding allele is restricted to a 
haplotype that carries the glucose-raising allele of another regulatory variant, which masks the true 
functional direction of the effect of p.Val219Leu [19]. These examples highlight the need for 
genetically matched control groups beyond ethnicity. Therefore, to characterize the human 
phenotype of variants in HNF1A, RFX6 and SLC30A8 described below, we employed a recall-by-
genotype setting involving cascade-testing to increase the number of carriers (stepwise recruitment 
of first-degree relatives of mutation carriers along as new carriers were identified) and recruitment 
of family-based controls, which enabled us to control for both background genetics and partially 





How to assess insulin secretion in vivo ?  
 
Caveats to consider 
Most studies rely on measurement of glucose and insulin in the blood circulation. However, the 
relationship between systemic concentrations of insulin and glucose is affected by many factors: 
glucose-sensing, secretory potentiators and inhibitors of insulin secretion, insulin-secretory 
capacity, glucagon secretion and endogenous glucose production, glucose uptake by the tissues, 
glucose effectiveness, glucosuria (reviewed in [3]). Furthermore, as the liver clears most of the 
secreted insulin during the first-pass transit from the pancreas, the systemic insulin concentration 
does not reflect total insulin secretion. Hence, C-peptide, secreted from beta cells in equimolar 
amount with insulin but with negligible hepatic clearance, is often measured instead. One should 
bear in mind that, C-peptide is sensitive to sample handling as it is quickly destroyed by proteases 
in fresh blood samples, and its long biological half-life (compared with insulin) precludes studying 
quick dynamic changes. The best option is to measure both insulin and C-peptide, which also 
allows estimating hepatic insulin clearance pending an adequate series of consecutive blood 
samples. 
 
One should also keep in mind that assessing insulin secretion in individuals with marked 
hyperglycaemia is unreliable as chronic hyperglycaemia inhibits insulin secretion [20]. Hence, the 
tests are usually restricted to those without overt hyperglycaemia (e.g. fasting glucose <10 mmol/l), 
which causes bias in the studies.  
 
A renewed interest has focused on proinsulin concentrations and proinsulin-to-insulin ratio, which 
has been considered an indicator of beta-cell stress or even a marker of the maximal beta-cell 
secretory capacity [21,22]. However, most of the original work on this ratio relied on 
radioimmunoassays employing polyclonal antibodies with major cross-reactivity. Thus, the 
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proinsulin assay detected both intact proinsulin and conversion intermediates (different des- and 
split-proinsulins), and the insulin assay detected also proinsulin and its conversion intermediates 
[21]. Back then, the ratio at least partly served as a way to obtain “clean” insulin concentrations. It 
is unclear how the ratios obtained with current, specific monoclonal assays correlate with the 
previous studies. In the same way, the old C-peptide assays also detected proinsulin. 
 
It takes three hours for 90% of the newly synthesized proinsulin to be converted to insulin in the 
beta-cell granules, and under stimulated conditions of elevated glucose as much as 50% of the 
newly synthesized (pro)insulin can be released within 3 hours [23]. Thus, both a primary 
impairment in proinsulin processing and an increased secretory demand on the beta cells could 
lead to an increased proinsulin-to-insulin ratio. Unfortunately, these mechanisms cannot be studied 
in vivo so we need to rely on the ratio. In this case, substituting insulin with C-peptide for the ratio 
might be beneficial as C-peptide escapes the clearance in the liver.  
 
 
Fasting samples, limited but straightforward view o n human physiology 
For practical reasons, large studies often rely on fasting blood samples to estimate beta-cell 
function. Indices derived from fasting plasma glucose and plasma/serum insulin or C-peptide 
provide a robust estimate of insulin secretion and sensitivity. HOMAβ is generally used for insulin 
secretion and HOMA-IR for insulin resistance ([24,25], available at 
www.dtu.ox.ac.uk/homacalculator, reviewed in [3,26]). The original computer model of 









, where concentration of glucose is given in mmol/l and insulin in 
µU/mL). Although the performance of these indices tends to be evaluated based on how well they 
correlate with results from glucose tolerance tests or clamp methods, one should keep in mind that 
fasting concentrations and those measured in response to a stimulus represent different aspects of 




It is essential to assess insulin secretion together with insulin sensitivity [26]. Although a 
normoglycemic insulin-sensitive individual has no physiological need to boost insulin secretion, the 
HOMAβ index could suggest impaired beta cell function if assessed without HOMA-IR (especially 
in individuals having both a low HOMAβ and low HOMA-IR, (Figure 1). On the other hand, in the 
context of normoglycaemia, mildly impaired insulin secretion could remain unexposed due to high 
insulin sensitivity. Further, these simple indices do not distinguish between different etiological 
mechanisms of hyperglycemia: an individual with life-long stable fasting hyperglycemia as a result 
of a GCK defect can score identically with a patient presenting with an early type 1 diabetes, as 
they both demonstrate fasting hyperglycemia and low or normal insulin concentrations. This is 
exemplified by a GAD-antibody-positive 31-year-old man presenting with HOMAβ of 26.4% 
(model)/16.6% (simple formula) and HOMAIR of 0.58/1.15 (fasting plasma glucose 7.6 mmol/l and 
insulin 3.4 mU/l) who later progressed to insulin-deficient T1D (C-peptide <0.01 nmol/l), whereas a 
44-year-old man with similar values (HOMAβ 26.5%/15.7%, HOMAIR 0.56/1.10, glucose 7.5 
mmol/l, insulin 3.3 mU/l), was diagnosed with GCK-MODY (Kettunen J, unpublished data from the 
Botnia Study). Obviously, the larger the study, the less these caveats affect the results, but one 
should be cautious when using these indices for individual assessment. 
 
Orally stimulated insulin secretion  
Compensatory mechanisms can maintain fasting normoglycemia despite modest disturbances in 
glucose metabolism, which can be unmasked with tolerance tests. The most commonly used – and 
the only universally standardized test - is the oral glucose tolerance test (OGTT), which is used for 
diagnosing diabetes and gestational diabetes. It involves a standard glucose dose (usually 75 g in 
adults) ingested in 5 minutes, and blood sampling at fasting and at 120 minutes for plasma glucose 
[28,29]. Additional sampling at 30 minutes or at other time points, complemented with 
measurements of serum insulin or C-peptide, allows calculation of various indices of insulin 
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 [31]) for 
insulin secretion, and the composite insulin sensitivity index (ISI or Matsuda index) for insulin 
sensitivity [32]. A disposition index (DI) can aid in relating secretion to sensitivity [3]. This is 
exemplified by a longitudinal analysis of a population study, where during the follow-up the insulin 
sensitivity decreased and, although CIR seemed to increase accordingly, the DI (CIR*ISI) actually 
decreased in those with T2D risk genotypes [33]. However, the equation for DI has not been 
standardized [3]. CIR or IGI at 30 minutes are considered surrogate measures of first-phase insulin 
secretion, although also the second-phase secretion already contributes at this stage [3]. During a 
tolerance test, glucose and insulin area under the curve (AUC) can serve as a proxy for the total 
glucose or insulin response. In addition, model-based indices provide more accurate estimates of 
glucose metabolism but they require sampling at multiple time-points (preferably at least seven) or 
time-points not usually included (like 90 minutes) [34–36].  
Figure 2 shows a comparison of OGTT-derived indices with fasting indices for insulin secretion and 
sensitivity. HOMA-IR correlates (inversely) rather well with the OGTT-derived insulin sensitivity 
index (ISI) in both diabetic and non-diabetic individuals, whereas the relationship between HOMAβ 
and either corrected insulin response (CIR30) or C-peptide response at 2 hours during the OGTT 
varies considerably, underlining the biological difference between fasting and stimulated insulin 
secretion. 
A mixed meal tolerance test [37–39] (MMTT) is a an alternative to an OGTT in a research setting, 
although it’s not being standardized hampers comparison of studies. Differing from OGTT, the 
mixed meal contains various carbohydrates but also protein and fat, which influence the insulin 
secretory response and glucose excursion and potentiate the incretin response. The same indices 
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for glucose and insulin secretion and insulin sensitivity can be applied to MMT as described for 
OGTT. 
Oral tests elicit physiological secretion of incretin hormones GLP-1 and GIP from enteroendocrine 
cells (reviewed in [6,17,40]). Incretins potentiate the insulin secretory response stimulated by 
glucose and amino acids resulting in a higher insulin secretion after an oral glucose stimulus 
compared with an i.v. glucose stimulus, which is called the incretin effect. The magnitude of the 
physiological incretin effect can be tested with an isoglycaemic clamp: the individual’s glucose 
response during an OGTT is replicated with an i.v. glucose infusion (resulting in exactly the same 
glucose levels as during the OGTT), and insulin response is measured.  A difference in insulin 
response during an OGTT or MMTT can result from defective incretin secretion or defective beta-
cell response to incretins as well as from a defective beta-cell response to glucose or amino acids. 
However, also differences in glucagon response to incretins, gastric emptying or intestinal 
absorption could play a role. The magnitude of the incretin secretory response can be estimated 
from serum/plasma samples, preferably collected in tubes containing dipeptidyl peptidase-4 
(DPP4) inhibitors [41]. However, the circulating concentrations of the hormones do not necessarily 
reflect the magnitude of the incretin effect on insulin-secretion, which is likely to be neurally 
mediated rather than a direct effect on GLP-1 or GIP receptors on the beta-cells [40]. The 
hormones are also rapidly cleared from the circulation and only a fraction reaches the pancreas. In 
any case, some genetic variants are known to affect circulating incretin concentrations [42–44]. 
The beta-cell response to incretins can be tested with administration of i.v. GIP or GLP-1. 
 
Intravenous stimulants of insulin secretion and act ion 
 
Although uncommon these days, i.v. glucagon bolus (1 mg) has also been used to promote insulin 
secretion mostly combined with a single measurement of C-peptide at 6 minutes, which has 
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substituted serial sampling [45–47]. Glucagon test is a robust method to assess insulin secretion 
capacity without the incretin effect, but typical adverse effects include nausea [3,4].  
I.v. glucose administration stimulates the beta-cells directly without an accompanying incretin 
effect. The most commonly used test involves an i.v. glucose bolus (0.3 g/kg body weight) and 
blood sample collection after the bolus at every 1-2 minutes during the first 10 minutes, and every 
5-10 minutes thereafter (intravenous glucose tolerance test, IVGTT). The sum of insulin values at 1 
and 3 minutes or the incremental insulin response during the first 10 minutes is considered to 
represent the first-phase insulin response, and the incremental insulin response from 20 min to 60 
min the second-phase insulin response. “Bergman’s minimal model” allows for estimation of insulin 
sensitivity (SI) and glucose effectiveness (SG) through repeated sampling after the i.v. glucose 
bolus [48], often with an additional bolus of insulin or sulphonylurea 20 min after the glucose bolus. 
SG is an insulin-independent measure for glucose to lower its own concentration, and SI an insulin-
dependent measure of glucose disappearance; they differentiate the physiological actions of both 
glucose and insulin to suppress endogenous glucose production and to increase glucose uptake in 
tissues. Some limitations and undermodelling of the minimal model can be overcome by replacing 
insulin measurements with C-peptide or using both combined (discussed in [36]). As an alternative 
to the minimal model, we have employed a combination of an IVGTT followed by a euglycaemic 
clamp (see below) during the same day, which provides estimates of both insulin secretion and 
insulin sensitivity (the Botnia clamp [49]).  
 
Refined phenotypes obtained with intravenous clamp studies  
  
A more powerful way to bring out differences in insulin secretion is a hyperglycemic clamp (HGC), 
which involves generating constant hyperglycemia (for example, 10 mmol/l [9]) through a 
continuous glucose infusion [9,50].  The rate of the infusion is determined by the insulin secretion 
rate (estimated from serum insulin concentration), insulin clearance (estimated from serum insulin 
and C-peptide concentration) and glucose uptake in tissues. However, the HGC can be criticized 
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for predisposing beta cells to unphysiological stress, and the immediate first-phase insulin 
response cannot be assessed by it. When studying patients with genetic variants that alter glucose 
sensing, like in GCK-MODY, measurement of insulin secretion at gradually increasing glycemic 
levels (a graded glucose infusion) [51,52], could provide valuable information on both glucose 
responsiveness and, if combined with arginine bolus at highest glucose, also maximal insulin 
secretion [2,9]. An even more powerful method to measure maximal insulin secretion capacity is 
combination of hyperglycaemia, GLP1-infusion and arginine boluses.  
 
A hyperinsulinemic euglycemic clamp (HEC)[50,53] is considered the gold standard to assess 
insulin sensitivity in vivo. A continuous insulin infusion raises serum insulin to a target level while a 
compensatory dynamically adjusted glucose infusion keeps plasma glucose constant (clamped), 
usually at 5.5–6.5 mmol/l. The glucose infusion rate in the steady state defines glucose uptake as 
a measure of insulin sensitivity. A variation with labelled glucose infusion (deuterium, tritium) 
provides an estimation of endogenous glucose production and, thereby, differentiating between 
hepatic and peripheral insulin sensitivity. When studying patients with genetic variants that alter 
glucose sensing, modifications of the glycaemic targets should be considered. For example, the 
routine clamping target of a HEC of 5.5 or 6.5 mmol/l is inappropriately low for some GCK gene 
defects [52,54]. 
The use of time- and resource-consuming clamp studies have usually been restricted to small 
studies or subcohorts focusing on clear disturbances in insulin secretion or insulin sensitivity. A 
mitochondrial DNA variant (m.3243A>G, causing mitochondrial diabetes) was reportedly 
associated with defective insulin secretion (by HGC, IVGTT, and arginine challenge) and 
decreased peripheral insulin sensitivity (by HEC) [55,56]. Monogenic HNF1A defects (resulting in 
HNF1A-MODY) are associated with reduced insulin secretion irrespective of study method (fasting 
samples, OGTT, IVGTT, HGC), while evidence on insulin sensitivity is somewhat contradictory 
[57–59]. Patients with HNF1B defects have reduced hepatic but normal peripheral insulin 
sensitivity [59]. An interesting approach was employed in a hypoglycaemic hyperinsulinemic clamp 
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study showing that in individuals with GCK-MODY, decrease of glucose concentration lead to an 
earlier decline in insulin secretion (C-peptide) and increase in glucagon and epinephrine secretion, 
as compared to individuals with type 2 diabetes (matched for fasting glycemia) and controls [52]. 
This suggests that the alpha-cell and the hypothalamic glucose sensing as well as the threshold for 
counterregulatory response is also impaired. 
Outside gene defects with manifest association with diabetes, research on less severe defects 
often require larger sample populations. A study on mechanistic associations of T2D-associated 
variants (JAZF1, CDC123/CAMK1D, TSPAN8/LGR5, THADA, ADAMTS9, NOTCH2/ ADAMS30, 
DCD, VEGFA, BCL11A, HNF1B, WFS1, and MTNR1B) in 336 participants had enough power to 
show an effect on insulin response during the HGC only for CDC123/CAMK1D, ADAMTS9, 
BCL11A, and MTNR1B (P<6.9x10-3) [60], while another study in 146 participants showed an 
association with a significant reduction in first-phase insulin secretion for CDKAL1 and IGFBP2 
[61]. Genetic studies utilizing an IVGTT include a GWAS study in 5,567 participants to characterize 
type 2 diabetes variants and their associated first-phase insulin secretion [62].  
 
What can monogenic diabetes teach us about genotype -
phenotype correlation?  
Before analyzing the evidence for beta cell dysfunction associated with the T2D gene variants, let 
us consider the human phenotype of the established monogenic variants associated with beta-cell 
dysfunction. Maturity-onset diabetes of the young (MODY) was initially a clinical diagnosis of early-
onset non-insulin dependent diabetes with a dominant pattern of inheritance [63,64], which largely 
has guided patient selection for genetic screening. Thus, most patients identified with a monogenic 
variant in HNF1A or HNF4A in the first wave used to have a typical MODY phenotype, including a 
defective insulin response to glucose and progression to diabetes at young age. However, the 
phenotypic associations have become less clear, when larger groups of either non-diabetic 
individuals or diabetic patients without an a priori clinical suspicion of MODY have been sequenced 
16 
 
for the MODY genes (see below). For example, despite conclusive in vitro data on the beta-cell 
effects of pathogenic HNF1A variants, the variation in the human phenotype of HNF1A-MODY 
remains puzzling. Why do some individuals with pathogenic variants in HNF1A develop diabetes at 
age 10, while others with the same variants might remain free of diabetes long after the age of 50?  
Nation-wide population studies provide a powerful tool to avoid ascertainment bias. A recent 
analysis of unselected data from the UK biobank revealed that less than 10 % of the heterozygous 
carriers of the HNF4A p.Arg114Trp were diabetic by the age of 40 years, which contradicts the 
data from MODY cohorts [65]. Another, partially population-based study in 2013 (with less 
conservative variant curation) found no association between pathogenic variants and diabetes [66] 
. However, while population-based studies potentially reduce ascertainment bias, they often lack 
systematic and repeated assessment of glycemic status. Without such systematic assessment, 
even monogenic diabetes might go unnoticed for years or decades, as patients with absent-to-mild 
symptoms hardly seek medical attention. Moreover, in some MODY subtypes, including HNF1A-
MODY and HNF4A-MODY, marked hyperglycemia might only occur after a stimulus (e.g. in 
response to carbohydrate load in OGTT or every-day meal) [51].  
Accordingly, among our families with the most common HNF1A-MODY variant (p.Gly292fs), the 
majority of the variant carriers had a diabetic value at 2 hours (65 patients), but only half of them 
had a diabetic fasting value (36 of 69 patients) during their first diabetic OGTT. HbA1c performed 
as poorly as fasting plasma glucose, as only 48% had a diabetic value (Unpublished data). Thus, 
diagnosing or excluding early diabetes in a carrier of a pathogenic HNF1A variant without an 
OGTT (or other test to stimulate insulin secretion) has the sensitivity of flipping a coin. Similarly, if 
studies solely depend on self-reported diabetes or diagnostic codes in hospital records, the 
sensitivity to estimate prevalent or incident diabetes is compromised [67–70]. Figure 3 illustrates 





An important but often neglected aspect to consider is the right time window for characterization of 
human physiology of the genetic defects as the pathophysiology is often age- or time-dependent. 
While most patients with HNF1A-MODY display a typical glucose and insulin response during 
OGTT (shown in the upper panel of Figure 4A), other carriers with exactly the same HNF1A variant 
can have quite normal insulin and glucose response (Figure 4A, lower panel). In some cases, even 
repeated testing well into adulthood fails to show typical phenotypic characteristics (data not 
shown). No obvious explanation springs up but the degree of glucosuria during the test, which is 
rarely measured, could play a role. Likewise, figure 4B shows variation in the OGTT response of 
GCK variant carriers (middle and lower panels of figure 4B). The variation in the human phenotype 
of the established monogenic beta-cell dysfunction genes forebodes problems for deciphering the 
phenotype of the common variants.  
 
T2D or low-penetrant MODY – the dilemma of RFX6 variants 
 
These phenotyping problems were evident in our study of protein-truncating variants (PTV’s) in 
RFX6 associated with what has been considered low-penetrant MODY [42]. Yet, for unknown 
reasons, PTVs in RFX6 appeared to lead to diabetes only in individual patients, whereas many 
carriers showed no obvious beta cell dysfunction. In this case, the difference between rare high-
risk T2D variants and variants causing low-penetrant monogenic diabetes is far from clear. One 
might even question, whether the dichotomous definition of having or not having diabetes is 
relevant to investigating these variants. Instead, maybe we should use comparative analyses of 
continuous glycemic or insulin secretion trait variables to evaluate the “diabetic potency” of a gene 
defect.  
Although neonatal diabetes caused by biallelic RFX6 defects results from disturbed pancreatic 
development [71,72], the mechanism of MODY associated with monoallelic RFX6 defects might 
involve other mechanisms. Although RFX6 directly regulates insulin production in beta cells [72], it 
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also increases GIP secretion from intestinal K cells [73]. Indeed, the PTV carriers had lower fasting 
and stimulated serum GIP concentrations compared to control individuals. Thus, PTVs in RFX6 
could contribute to diabetes also indirectly via GIP-mediated effect on islet-function through 
eliciting insulin secretion from beta cells and glucagon secretion from alpha cells as well as through 
promoting beta cell survival. To date, the indirect effects on pancreatic function e.g. via the incretin 
or nerve system have not really been studied with respect to any genetic variants considered to 
affect beta-cell function [74]. 
 
 
Common variants associated with beta-cell function  
 
A genetically programmed failure of the beta cell to compensate for insulin resistance is considered 
the main culprit in T2D [75]. Accordingly, of the more than 400 genetic variants associated with 
T2D in GWAS studies, a large proportion appears to influence insulin secretion [76–78]. However, 
considering the minimal individual effect of the variants on diabetes risk or insulin secretion, very 
large cohorts are required to prove an association. Hence, most of the evidence for beta-cell 
dysfunction inevitably relies on association of the variants with rather simple phenotypic traits 
based on fasting measurements of glucose and insulin, sometimes complemented with C-peptide 
or proinsulin [22]. The caveats discussed above apply, measures of insulin secretion are rarely 
adjusted for insulin sensitivity even in non-diabetic cohorts and stimulatory tests tend to be 
available only for subgroups. Thus, it is difficult to make the step from an association between a 
variant and plasma concentration of glucose and insulin, or indices calculated from them, to the 
interpretation that the variant would be associated with decreased insulin secretion and not 
increased insulin sensitivity. Recent approaches applying soft clustering on a number of traits only 
partly circumvent these problems [77,79].  
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Instead of reviewing data for all variants associated with insulin secretion in different studies (for 
detailed trait associations, see [22]), we concentrate on the variants Mahajan et al. [77] found to 
affect insulin secretion through clustering analysis in a meta-analysis. Twenty-one variants were 
associated with insulin secretion (Supplementary figure 6B in [77]; eight also with high proinsulin 
and 21 with low proinsulin), whereas another 35 variants were considered likely to have an impact 
on both insulin secretion and insulin action. Based on the results reported by Mahajan for different 
traits [77], we set out to re-explore the clinical evidence for an insulin-secretory defect. In this 
exercise, we included the 25 variants with data available for corrected insulin response adjusted for 
insulin sensitivity during an OGTT (CIR*ISI, N∼5000), HOMAβ (N∼46,000), 2-hour glucose 
(N∼50,000) and proinsulin (N∼10,000), and either P<1x10-4 for any of the traits, or nominally 
significant (P<0.05) association in case of CIR*ISI or proinsulin (Table 1, Supplementary table 11 
in [77]). Note that data for different traits might have come from different cohorts in the meta-
analysis, and the same individuals were not necessarily tested for all included traits.  
Considering either low CIR*ISI or a combination of low HOMAβ and high 2-hour glucose as strong 
evidence of decreased insulin response to glucose (2-hour insulin was not available), a significant 
association was considered for nine of the “insulin secretion” variants in (or near) MTNR1B, 
CDKAL1, HHEX-IDE, CDKN2A-B, SLC30A8, TCF7L2, ANK1, and GCK (Table 1). Obviously, a 
similar phenotype could also result from increased hepatic clearance, as shown for another 
CDKAL1 variant with an association with insulin clearance [80]. Another three variants were 
strongly associated with 2-hour glucose and modestly with HOMAβ (ADCY5, IGF2BP2) or vice 
versa (GLIS3) - but not with measures of insulin sensitivity - and thereby considered to imply 
“probable insulin secretory defect”. Regarding the variants associated only with 2-hour glucose, we 
considered the association possible evidence for defective insulin response to glucose (“possible 
insulin secretory defect”), as the variants were not associated with insulin resistance (estimated 
with HOMA-IR or ISI, P>0.05, Supplementary table 11 in [77]). Independent data for corroboration 
of these findings are challenging to find, because most large cohorts have been included in these 
meta-analyses in the first place. It also needs to be pointed out that some quite established beta-
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cell genes like KCNJ11 were not included in this analysis. Obviously, the rest of the variants 
included in the clusters could still be associated with clinically significant insulin secretory defects 
in humans, but more in vivo data would be needed to prove it. Whether we can upgrade 
association to causality regarding these variants and beta-cell function, depends on functional 
studies (beyond the scope of this review). 
The available data do not allow for differentiating defective glucose-sensing from incapacity to 
synthesize, process or secrete proinsulin/insulin (including paucity of beta-cells). No direct 
association could be shown with single variants and proinsulin concentration in the subcohort of 
10 000 individuals with proinsulin data (except perhaps for rs7903146 [TCF7L2]; P=0.00464, and 
rs1359790 [SPRY2]; P=0.0042; Table 1). However, the genetic variants associated with T2D and 
insulin secretion have been reported to fall in two seemingly different clusters, one associated with 
low, and the other with high proinsulin, suggesting mechanistic differences behind insulin 
deficiency [77,79,81]. Udler et al. showed that genetic risk scores (GRS) based on the clusters 
were associated with decreased or increased proinsulin (P<10-17) [79]. Four of the variants 
included in the GRS (in/near TCF7L2, SLC30A8, C2CD4A-B, CENTD2 a.k.a. ARAP1/ STARD10) 
have previously shown significant association with fasting proinsulin concentration adjusted for 
insulin [81]. Regarding the TCF7L2, SLC30A8 and C2CD4A-B variants, the proinsulin-raising allele 
was seen together with higher 32,33-split proinsulin, lower fasting insulin, higher fasting glucose 
and lower IGI during the OGTT - originally interpreted to suggest dysfunction in the early steps of 
insulin synthesis. However, in case of the variant in SLC30A8 (rs11558471, which is in linkage 
disequilibrium with rs13266634 discussed below), it seems that in fact the major allele (with a C at 
rs13266634, referred to as Trp325 below) actually enhances proinsulin processing thus decreasing 
proinsulin-insulin and proinsulin-C-peptide ratio [18]. Interestingly, an association was also seen 
with PCSK1, which encodes the prohormone convertase.  
 
 




The common missense variant (rs13266634, c.973T>C, p.Trp325Arg) in the SLC30A8 gene, 
encoding the Zinc transporter 8 (ZnT8), was among the first variants strongly associated with T2D 
risk with an OR of 1.18 for the arginine allele [82]. However, since then, several studies and meta-
analyses have verified that actually the minor allele at this position lowers T2D risk, fasting glucose 
(P=1.63x10-46) and HbA1c (P=8.5x10-28) [77]. Moreover, SLC30A8 harbours more than 30 low-
frequency loss-of-function (LoF) or missense variants conferring protection against T2D [83]. 
Indeed, based on their series of protective alleles, Flannick et al.[83] argued that decreased T2D 
risk was the typical effect of SLC30A8 missense variation and not unique to haploinsufficiency, as 
was first presumed when the p.Arg138* (rs200185429, c.412C>T) and p.Lys34Serfs*50 
(rs587777582, c.101_107del) were found to confer 53%-80% protection against T2D [84]. 
Although the encoded protein, ZnT8, is directly connected to insulin secretion, being responsible 
for insulin transport to the secretory vesicles and hexamer formation, the mechanism behind the 
protection remained unclear for a long time – much due to the conflicting results from animal and in 
vitro studies. It took us five years to recruit enough LoF carriers and related non-carriers through 
cascade screening and to complete a detailed metabolic testing to prove the physiological 
consequences of the p.Arg138* variant[18]. In the end, we could show that rare p.Arg138*, and to 
a lesser extent major common variant allele (Trp325) were associated with a higher insulin 
secretory response during OGTT and test meal (Trp325 also during an IVGTT), whereas the 
carriers had no differences in glucagon, GLP-1 or free fatty acid response compared with family- or 
population-based controls [18]. Lower proinsulin/C-peptide and proinsulin/insulin ratios suggested 
effects on proinsulin conversion as a mechanistic explanation in addition to an enhanced insulin 
responsiveness to glucose.   
 
However, the story may be more complex. Circulating zinc levels have also been associated with 
diabetes (reviewed in [85]). Moreover, a report in 1796 individuals (785 T2D patients) from China 
showed that an inverse association of plasma zinc concentration with T2D was modified by the 
p.Trp325Arg genotype [86], but to our knowledge, no one has tried to replicate that finding. We 
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found no clear correlation between circulating zinc concentration and insulin secretion or presence 
of p.Arg138* or p.Trp325Arg in a small subset of participants who had data for zinc concentrations 
[18]. Unfortunately, retrospective analysis in larger cohorts from stored samples is not possible as 
the measurement of zinc or other trace elements requires that samples be collected in special 
tubes, and the zinc concentration must be adjusted for copper and albumin concentration. 
Considering the potential of the ZnT8 for pharmacological intervention, studies on the effect of zinc 
consumption are called for. 
 
 
Controversies around MTNR1B 
 
Melatonin is synthesized from serotonin in a circadian manner mainly in the pineal gland with the 
highest circulating levels at night and low values during the day. The synthesis and direct secretion 
is under the control of the central biological clock, which, in turn, is regulated through feed-back 
mechanism by the rhythmic melatonin pulses, which also serve to influence the circadian 
regulation of peripheral tissues [87]. Circulating levels of melatonin peak at ∼200 pg/ml in the 
middle of the night and drop to ∼10 pg/ml during day time; the half-life of the hormone in the 
circulation is less than 20 min. Melatonin has a direct inhibitory effect on insulin release but also a 
stimulatory effect on glucagon secretion (reviewed in [88]). 
 
A non-coding variant rs10830963 in the MTNR1B gene, encoding the melatonin receptor 1B, has 
shown consistent association with the risk of T2D, increased fasting glucose and HbA1c (but not 2-
hour glucose during OGTT) as well as with decreased early insulin response to glucose in several 
studies [77,89–91]. Each G allele of the variant increases the risk of T2D by OR of 1.09 (95% CI 
1.05;1.12) and fasting plasma glucose by 0.07 mmol/l (95% CI 0.06;0.08) [91]. Similarly, a 
consistent allele dose-dependent decrease in early insulin secretion has been shown in non-
diabetic individuals from several cross-sectional studies: OGTT-based measurements in the 
Finnish Botnia, PPP-Botnia, METSIM and Helsinki Birth Cohort studies (N=11,601, CIR) [90], and 
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the Danish Inter99 Study [91] (N=5553, insulinogenic index), and an impaired insulin response 
during IVGTT (FPIR, AIR) in the Botnia (N=505), FUSION (N=522) and Inter99 (N=5553) studies. 
Also, longitudinally, each G allele was associated with an increase in FPG and with a decrease in 
CIR and DI between baseline and follow-up in the Botnia Prospective and PPP-Botnia studies but 
not with changes in HOMA-IR or ISI [90]. 
 
While the association of the risk variant with increased fasting glucose and decreased insulin 
secretion is well established, the suggested effect on insulin-sensitivity is less clear. An association 
with decreased insulin sensitivity (ISI, beta -0.04, SE 0.012, P=6.3x10-4) was seen in non-diabetic 
individuals from the population-based PPP-Botnia study (N=4654) at baseline [92]. The effect was 
roughly of the same size, but statistically insignificant in the subgroup with follow-up OGTT data 
(N=3422; ISI at baseline/follow-up: -0.047 (95%CI-0.093; 0.000) / -0.032 (-0.081; 0.017) [93]. On 
the other hand, Sparsø et al.[91] found no association with fasting or OGTT-based measures of 
insulin sensitivity (HOMA-IR, BIGTT-Si) in the Inter99 Study, nor with whole-body insulin sensitivity 
measured with euglycaemic hyperinsulinemic clamp in a small group of elderly individuals (N=77). 
However, they reported an association with decreased hepatic insulin sensitivity in the latter group. 
Further, a recent meta-analysis of GWAS data found no association with either HOMA-IR 
(N=46186) or ISI (N=5318) [77]. The effect, if there is one, is in any case smaller than that on 
insulin secretion. Such a small effect would be difficult to see unless the genotype groups were 
well matched, as many confounding factors predominantly affect insulin sensitivity (BMI, exercise, 
quality of sleep, other stress factors). Of note, no association has been observed with the risk 
variant and quality of sleep [93,94]. One confounding factor could be seasonal variation in day-light 
length, which has been reported to interact with the association between the variant and metabolic 
parameters [93,95], although more studies are needed to prove this.  
 
Outside the central nervous system (CNS) and retina [90,96], MTNR1B is predominantly 
expressed in the pancreatic beta-cells [96]. A mechanistic explanation linking the clinical 
phenotype to the non-coding variant came from studies showing that the rs10830963 risk variant 
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leads to increased expression of the receptor in beta-cells and increased signaling through the 
receptor, which in turn was associated with lower insulin-secretion [90,94]. In line with this, an 
intervention with a daily dose 4 mg of melatonin for three months led to a decrease in insulin 
secretion and an increase in glucose level in all individuals but particularly in the risk genotype 
carriers in a small recall-by-genotype-based study (N=23 with GG, 22 with CC genotype) nested in 
the PPP-Botnia Study [94]. Similar results regarding inhibitory effect on insulin secretion, were 
obtained in an acute dosing (5 mg) study on 17 (11 CG, 6 CC) individuals [97]. However, these 
results are difficult to combine with data on rare LoF variants leading to decreased receptor 
signaling, which are also associated with risk of T2D, even more strongly than the common variant 
[98,99]. Among the 40 non-synomous variants described by Bonnefond et al. [99], 24 very rare 
variants (MAF <0.1%) showed decreased receptor function: four led to total loss of function 
(p.Ala42Pro, p.Leu60Arg, p.Pro95Leu and p.Tyr308Ser), and 19 displayed impaired spontaneous 
or melatonin-induced activation of the G-proteins coupled to the receptor or reduced spontaneous 
beta-arrestin recruitment [98,99].The variants with defects in melatonin-induced activation of the 
receptor were strongly associated with increased T2D risk (OR 3.25, 95% CI 1.73; 6.10, P =2.4 × 
10−4). An interesting finding was that some variants also affected the spontaneous receptor activity, 
which was also associated with T2D risk. Notably, one of the variants showed a robust gain-of-
phenotype. Unfortunately, no data on human physiology are available for these interesting 
variants. Without such data, the dispute on whether too much or too little melatonin signaling in the 
beta-cells predisposes to diabetes, is hard to solve [100,101]. Perhaps both views are true. 
Obviously the “crime-scene” does not even need to be in the islets, it could also be in other tissues, 
e.g. the CNS with high level of MTNR1B expression. 
 
 
Another contradictory topic is, whether excess melatonin is good or bad for glucose-control. 
Melatonin can affect insulin secretion directly, but it can also affect glucose levels through non-
beta-cell mechanisms - direct effects on glucose uptake, glucagon secretion, glycogen synthesis 
and inhibition of adrenocorticotropic hormone (ACTH) secretion have been proposed [87,102]. 
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Lower melatonin secretion was independently associated with a higher risk of developing type 2 
diabetes in a nested case-control study within the Nurses’ Health Study cohort [103]. Compared 
with women in the highest ratio category of urine 6-sulfatoxymelatonin to creatinine (reflecting 
melatonin secretion during the night), those in the lowest category had a multivariable odds ratio of 
2.17 (95% CI, 1.18-3.98) of developing type 2 diabetes. Besides that study, human in vivo 
metabolic data are scarce, and melatonin treatment trials have included small numbers of patients 
suffering from various conditions that can themselves affect glucose control [102]. For example, if 
melatonin treatment in an anxiety disorder led to better glycaemic level, that could be due to 
melatonin affecting glycaemia (e.g. via insulin secretion) or due to reducing anxiety and thus 
increasing insulin sensitivity. Acute and long-term effects as well as effects of small or high-dose 
treatment can differ.  
 
Conclusions and perspectives 
While modern techniques have revealed a multitude of genetic defects associated with diabetes, 
detailed human data on related beta-cell dysfunction are scarce and seldom analyzed in relation to 
the need of insulin, (insulin sensitivity). The genetic defects associated with beta-cell dysfunction 
can impact either structural (beta-cell mass) or functional (insulin secretion) fate of beta-cells – or 
both. Efforts to distinguish between these two dimensions are crucial in order to understand the 
pathogenesis of diabetes. Hence, beta-cell specific radioligands and imaging techniques that 
would allow for in vivo functional imaging of beta-cell mass and function are called for. 
Human studies on type 2 diabetes often promote a simplified view on homogeneous beta-cells 
working in isolation. However, the approach neglects various physiological factors. Recent studies 
suggest operational heterogeneity among the beta-cells: a fraction of beta-cells in an islet 
resembles pacemakers as they orchestrate overall response to glucose [104]. Further, even in 
adults, beta-cells might lose cellular identity, and evidence is mounting on beta-cell de-
differentation and trans-differentation [105]. Without the possibility to obtain biopsies, these 
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phenomena are practically impossible to study in vivo. Hopefully they can be addressed with 
studies involving biomarkers or liquid biopsies utilizing exosomal RNA from plasma or urine [106]. 
It is worth emphasizing, that beta-cells also interact with other cells in the endocrine and exocrine 
pancreas [107,108] as well as other organs – through hormonal and neural signals. A key hormone 
of glucose homeostasis, glucagon has attracted little attention compared to insulin, despite 
inappropriate hyperglucagonemia featuring in both type 1 and type 2 diabetes [109,110]. An 
interesting example is a variant in the PCSK2 gene reported to decrease both insulin and glucagon 
secretion, which would have counteracting effects on glucose concentrations [111]. 
Finally, derangement of the pulsatile pattern of secretion of insulin and glucagon in diabetic 
individuals is an area not captured with the phenotyping efforts of today [112,113].  
 
How should future studies be designed?  
It would be important to develop shared protocols between study groups for detailed phenotyping 
of carriers of the identified variants and carefully matched control groups. Such protocols should 
use different stimuli and suppressors of insulin and glucagon secretion together with dynamic 
functional imaging. Similarly to pipelines and algorithms for genetic curation of the variants, we call 
for standardized pipelines for phenotypic studies.  
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Figure and table legends 
TABLE 1. A clinical assessment of the overall strength of the evidence for an association with an 
insulin secretion defect of selected genetic variants. Data are from the clustering analysis by 
Mahajan et al.[77], who found 29 variants associated with insulin secretion, eight were associated 
with high proinsulin (cluster 1) and 21 with low proinsulin (cluster 2), whereas another 35 variants 
were considered likely to have an impact on both insulin secretion and insulin action (cluster 3); 
(Supplementary figure 6B in [77]). We included the variants with data available for corrected insulin 
response adjusted for insulin sensitivity during an OGTT (CIR*ISI), HOMAβ, 2-hour glucose and 
proinsulin, and either P<1x10-4 for any of the traits (shown in green), or nominally significant 
(P<0.05) association in case of CIR*ISI or proinsulin (shown in yellow) (data from Supplementary 
table 11 in [77]). HOMA-IR P>0.05 for all associations except SPRY2 (0.0097), for ISI P>0.05 for 
all associations except for GIPR (>0.02) and SPRY2 (0.0036) (data not shown, see supplementary 
table 11 in [77]). 
FIGURE 1. The relationship between HOMAβ (insulin secretion) and HOMA-IR (insulin sensitivity) 
in the PPP-Botnia Study [114] (of 3706 individuals, 3463 visualized within the display range), a 
population-based study in Western Finland. Closed black circles (●) represent individuals with 
normoglycemia (FPG ≤ 5.5 mmol/l) and good insulin sensitivity (defined as HOMA-IR ≤ 1.0), and 
open grey circles (○) represent other participants. Clearly, HOMAβ alone tells little about the insulin 
secretion capacity of the normoglycemic individuals as the values are scattered along the axis for 
HOMAβ, which highlights the importance to assess insulin secretion together with insulin sensitivity 
and glycemic status.      
FIGURE 2. Comparison of estimates of insulin sensitivity (panels A and B) and insulin secretion 
(panels C-F) based on samples taken at fasting (HOMA-IR, HOMAβ) or during an OGTT (ISI30, 
CIR, 2-hour C-peptide) in individuals with (left panels, N=109-114) or without (right panels, 
N=3336-3439) diabetes from the population-based PPP-Botnia Study [114]. Diabetes was defined 
as FPG ≥ 7 mmol/l. Cases with extreme values were excluded (FGP ≥ 10 mmol/l, CIR < 0.25 or > 
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100, HOMA-IR > 16, ISI < 10, or 2-hour C-peptide > 5 nmol/l). HOMA-IR inversely correlates rather 
well with the OGTT-derived insulin sensitivity index (ISI, based on 0-, 30-, and 120-minute values) 
in both diabetic (panel A) and non-diabetic (panel B) individuals, whereas correlation of HOMAβ 
with either corrected insulin response at 30 minutes (CIR, panel C for diabetic and panel D for non-
diabetic) or C-peptide response at 2 hours during an OGTT (panel E for diabetic and panel F for 
non-diabetic) is rather poor especially in non-diabetic individuals, underlining the biological 
difference between fasting and stimulated insulin secretion. 
FIGURE 3. Age at diagnosis of diabetes differs largely among heterozygous carriers of the 
monogenic HNF1A variant (p.Gly292fs) from three big Finnish families (previously families B, C, D 
in [49]). Family members born in the later years were diagnosed earlier than those born earlier. 
After it had become apparent that the risk of diabetes was particularly high in these families, the 
finding is probably explained by an increased awareness and familial screening rather than an 
actual change in phenotype. The year 1975 was chosen as the cut-off to allow a sufficient number 
in both groups (~2/3 before and 1/3 after the year). 
FIGURE 4A. Examples of heterogeneity in glucose and insulin responses during an OGTT in 
selected carriers heterozygous for the most common HNF1A-MODY variant p.Gly292fs. Patient 
#1: A 28-year-old lean woman has an OGTT response characteristic for HNF1A-MODY: fasting 
euglycemia precedes a steep post-challenge increase in plasma glucose, whereas the insulin 
response is relatively flat. Patient #2: a 33-year-old man with metabolic syndrome also shows a 
characteristic OGTT response for HNF1A-MODY (BMI 35 kg/m2, waist circumference 110 cm, 
serum triglycerides 3.73 mmol/l, HDL cholesterol 0.85 mmol/l, hypertensive blood pressure). 
Patient #3: a 29-year-old man has a good insulin response and surprisingly steady euglycemia 
throughout the OGTT despite the pathogenic HNF1A variant and obesity (BMI 33 kg/m2).  
 
FIGURE 4B. Heterogeneous glucose and insulin responses during an OGTT in selected carriers of 
pathogenic GCK variants. Patient #4: A 19-year-old lean man shows an OGTT response 
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characteristic for GCK-MODY (p.Val181Ala): mild fasting hyperglycemia and low fasting insulin 
concentration followed by a mild rise in glucose, which triggers an insulin response at 30 minutes. 
Patient #5: Some patients like this lean 46-year-old woman (#5) with a more drastic p.Gly261Arg 
variant [115–117] presented with marked post-challenge increase in glucose and weak insulin 
secretory response. Patient #6: A 45-year-old man with p.Met235Thr and metabolic syndrome 
(dyslipidemia, hypertension, waist circumference of 101 cm and BMI of 28 kg/m2) demonstrates a 
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Variant Insulin secretion cluster Overall evidence for  CIR*ISI HOMAβ 2-hr glucose Proinsulin 
insulin secretion defect N∼5000 N∼46000 N∼50000 N∼10000 
Low CIR (30 min insulin response) Beta SE P-value Beta SE P-value Beta SE P-value Beta SE P-value 
MTNR1B rs10830963 1 STRONG -0.190 0.0250 4.73x10⁻¹⁴ -0.0390 0.00400 8.60x10⁻²³ -0.00251 0.00968 0.796 -0.00400 0.00470 0.399 
CDKAL1 rs7756992 2 STRONG -0.110 0.0230 8.13x10⁻⁷ -0.00950 0.00360 0.00754 0.0422 0.00973 2.59x10⁻⁵ -0.0110 0.00420 0.0107 
HHEX-IDE rs5015480 2 STRONG -0.100 0.0220 3.05x10⁻⁶ -0.00470 0.00330 0.157 0.0372 0.00878 3.17x10⁻⁵ 0.00130 0.00390 0.733 
C2CD4A-B rs4502156 2 STRONG -0.100 0.0220 3.74x10⁻⁶ -0.00990 0.00340 0.00357 -0.0475 0.00884 1.84x10⁻⁸ -0.00170 0.00390 0.669 
CDKN2A-B rs10965250 2 STRONG -0.110 0.0300 0.000493 -0.00760 0.00450 0.0886 0.0328 0.0126 0.00868 0.00310 0.00510 0.545 
WSCD2 rs3764002 3 PROBABLE -0.0950 0.0310 0.00194 0.00620 0.00420 0.138 -0.00490 0.00969 0.615 -0.00300 0.00510 0.560 
SLC30A8 rs13266634 1 STRONG -0.0700 0.0240 0.00408 -0.0160 0.00380 2.36x10⁻⁵ 0.0165 0.00936 0.0991 -0.00360 0.00460 0.441 
TCF7L2 rs7903146 1 STRONG -0.0660 0.0250 0.00876 -0.0200 0.00380 1.39x10⁻⁷ 0.0845 0.0102 1.58x10⁻¹⁸ -0.0120 0.00430 0.0046 
BCAR1 rs7202877 3 -0.0830 0.0340 0.0154 -0.00340 0.00530 0.524 0.0374 0.0137 0.00431 -0.00600 0.00630 0.339 
ANK1 rs516946 2 STRONG -0.0500 0.0250 0.0444 -0.0130 0.00380 0.000529 0.0414 0.0103 5.60x10⁻⁵ -0.00930 0.00430 0.0318 
Low HOMAβ and high 2h-glucose 
GCK rs730497 1 STRONG -0.0600 0.0330 0.0732 -0.0250 0.00460 3.84x10⁻⁸ 0.100 0.0124 9.21x10⁻¹⁷ 0.00570 0.00530 0.279 
ADCY5 rs11708067 1 STRONG -0.0290 0.0290 0.319 -0.0160 0.00430 0.000177 0.0892 0.0107 4.26x10⁻¹⁷ -0.00310 0.00490 0.530 
CENTD2 rs11603334 2 POSSIBLE -0.0170 0.0280 0.550 -0.0160 0.00420 0.000138 0.0338 0.0114 0.00179 -0.0120 0.00510 0.0227 
GLIS3 rs10758593 2 POSSIBLE -0,022 0.0210 0.308 -0.0150 0.00330 1.33x10⁻⁵ 0.0257 0.00887 0.00387 -0.00640 0.00390 0.0995 
High 2h-glucose 
HNF1A rs1169288 1 POSSIBLE -0.0580 0.0230 0.0107 -0.00560 0.00350 0.111 0.0605 0.0108 7.86x10⁻⁹ -0.00510 0.00410 0.211 
GIPR rs8108269 3 POSSIBLE -0.0450 0.0260 0.0806 -0.00260 0.00410 0.531 0.0389 0.0103 5.25x10⁻⁵ -0.00220 0.00480 0.655 
ABO rs505922 1 POSSIBLE -0.0360 0.0220 0.105 -0.00170 0.00340 0.612 0.0491 0.00919 2.31x10⁻⁸ 0.00290 0.00400 0.474 
GIPR rs1800437 3 POSSIBLE -0.0420 0.0330 0.209 0.000800 0.00440 0.858 0.103 0.0108 2.59x10⁻²³ -0.00400 0.00520 0.446 
IGF2BP2 rs7633675 2 PROBABLE -0.0270 0.0230 0.232 -0.0110 0.00350 0.00187 0.0499 0.0103 6.65x10⁻⁷ -0.00520 0.00410 0.205 
MLX rs665268 3 POSSIBLE -0.0150 0.0250 0.556 0.00690 0.00370 0.0601 0.0422 0.0100 3.59x10⁻⁶ 0.00700 0.00430 0.101 
KCNQ1 rs2237892 2 POSSIBLE -0.0200 0.0490 0.682 -0.0200 0.00730 0.00578 0.0607 0.0177 0.000187 -0.0190 0.00860 0.0305 
Low HOMAβ or proinsulin 
DGKB rs2191349 2 POSSIBLE -0.0100 0.0200 0.609 -0.0210 0.00330 5.04x10⁻¹¹ 0.00142 0.00879 0.791 -0.00500 0.00380 0.188 
PROX1 rs340874 2 POSSIBLE -0.0310 0.0220 0.147 -0.0140 0.00340 3.43x10⁻⁵ 0.0233 0.00885 0.0166 -0.00850 0.00410 0.0365 
SPRY2 rs1359790 3 0.0230 0.0230 0.304 -0.00880 0.00360 0.0158 0.0109 0.00969 0.194 -0.0120 0.00420 0.00424 
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Figure 4A and 4B
Human physiology of the numerous genetic variants, associated with diabetes-related 
traits, has been poorly characterized.  
Few variants can unequivocally be interpreted to be associated with defective insulin 
secretion across studies.  
The different dysregulated processes, leading to beta-cell dysfunction, cannot be studied 
directly, so we need to rely on proxies and indices based on measuring blood samples. 
Insulin secretion should be evaluated in parallel with insulin sensitivity  
The available tests cannot distinguish between reduced beta-cell mass and defective beta-
cell function. 
 
